Cargando…

P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.

Detalles Bibliográficos
Autores principales:	Luca Morelli, Gian, Fili, Carla, Mauro, Endri, Maria Scattolin, Anna, Mosna, Federico, Gurrieri, Carmela, Nadali, Gianpaolo, Lico, Albana, Sperotto, Alessandra, DE Bellis, Eleonora, Michieli, Mariagrazia, Aloisi, Teresa, Lazzarotto, Davide, Elena Zannier, Maria, Simeone, Erica, Alzetta, Daniel, Battaglia, Giulia, Callegari, Chiara, Pizzano, Umberto, Mullai, Rikard, Tosoni, Luca, Tiribelli, Mario, Fanin, Renato
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429036/ http://dx.doi.org/10.1097/01.HS9.0000969104.08302.5e

Ejemplares similares

PB2214: CORRELATION BETWEEN HEMORRHAGIC EVENTS AND IPSET SCORE IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
por: Tosoni, Luca, et al.
Publicado: (2023)

PB1860: HIGH EFFICACY OF HYPOMETHYLATING AGENTS PLUS VENETOCLAX COMBINATION THERAPY IN ELDERLY PATIENTS AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY: A REAL-LIFE EXPERIENCE.
por: Zannier, Maria Elena, et al.
Publicado: (2023)

Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and P. aeruginosa
por: Cojutti, Pier Giorgio, et al.
Publicado: (2020)

BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC”
por: Di Giusto, Sara, et al.
Publicado: (2022)

CPX-351 in FLT3-mutated acute myeloid leukemia
por: Andrews, Claire, et al.
Publicado: (2023)

Emergency stroke management during COVID-19 pandemic: Experience from Triveneto area
por: Scali, Ilario, et al.
Publicado: (2021)

Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo
por: Vincelette, Nicole D., et al.
Publicado: (2019)

Population Pharmacokinetics and Exposure‐Response Analyses for CPX‐351 in Patients With Hematologic Malignancies
por: Wang, Qi, et al.
Publicado: (2018)

CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies
por: Hu, Yixin, et al.
Publicado: (2022)

CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML
por: Molica, Matteo, et al.
Publicado: (2022)

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
por: Matthews, Andrew H., et al.
Publicado: (2022)

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
por: Rautenberg, Christina, et al.
Publicado: (2021)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

CPX‐351 (Vyxeos(®)) can cause severe rash in acute myeloid leukemia—A case report
por: Urbantat, Ruth M., et al.
Publicado: (2021)

Pulmonary Actinomycosis by Actinomyces graevenitzii in Two Hematologic Patients
por: Facchin, Gabriele, et al.
Publicado: (2023)

CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program
por: Guolo, Fabio, et al.
Publicado: (2020)

Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study
por: Cojutti, Pier Giorgio, et al.
Publicado: (2020)

The two-component system CpxA/CpxR is critical for full virulence in Actinobacillus pleuropneumoniae
por: Liu, Feng, et al.
Publicado: (2022)

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties
por: Mayer, Lawrence D, et al.
Publicado: (2019)

Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible
por: Vucinic, Vladan, et al.
Publicado: (2020)

Successful Treatment of Acute Myeloid Leukemia with CPX-351 in 2 Patients in the United Kingdom during the COVID-19 Pandemic
por: Munisamy, Sreetharan, et al.
Publicado: (2021)

P516: CARDIOTOXICITY OF CPX-351 VS 7 + 3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA
por: Mitchell, Joshua D., et al.
Publicado: (2023)

Interactions of the CpxA sensor kinase and cognate CpxR response regulator from Yersinia pseudotuberculosis
por: Thanikkal, Edvin J, et al.
Publicado: (2012)

The CpxA/CpxR Two-Component System Affects Biofilm Formation and Virulence in Actinobacillus pleuropneumoniae
por: Li, Huan, et al.
Publicado: (2018)

The Virulence Effect of CpxRA in Citrobacter rodentium Is Independent of the Auxiliary Proteins NlpE and CpxP
por: Giannakopoulou, Natalia, et al.
Publicado: (2018)

The CpxA/CpxR two-component system mediates regulation of Actinobacillus pleuropneumoniae cold growth
por: Yao, Qing, et al.
Publicado: (2022)

A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias
por: Lin, Tara L., et al.
Publicado: (2019)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
por: Ilyas, Rimal, et al.
Publicado: (2023)

Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML
por: Uy, Geoffrey L., et al.
Publicado: (2022)

Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro
por: Fortin, Marie C., et al.
Publicado: (2023)

PB1763: THE CELLULAR UPTAKE OF CPX-351 BY SCAVENGER RECEPTOR CLASS B TYPE 1-MEDIATED NONENDOCYTIC PATHWAY IN LEUKEMIA CELLS.
por: Araie, Hiroaki, et al.
Publicado: (2023)

Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience
por: Fianchi, Luana, et al.
Publicado: (2023)

Identification of cpxS mutational resistome in Pseudomonas aeruginosa
por: Tian, Zhe-Xian, et al.
Publicado: (2023)

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
por: Othman, Jad, et al.
Publicado: (2023)

Dynamic Interaction between the CpxA Sensor Kinase and the Periplasmic Accessory Protein CpxP Mediates Signal Recognition in E. coli
por: Tschauner, Karolin, et al.
Publicado: (2014)

CpxA Phosphatase Inhibitor Activates CpxRA and Is a Potential Treatment for Uropathogenic Escherichia coli in a Murine Model of Infection
por: Fortney, Kate R., et al.
Publicado: (2022)

CPX 반복 시행에 따른 영역별 성적의 변화
Publicado: (2011)

CPX 도입에 따른 의과대학생들의 환자중심적 태도 변화
Publicado: (2014)

Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax
por: Candoni, Anna, et al.
Publicado: (2022)

A connecter-like factor, CacA, links RssB/RpoS and the CpxR/CpxA two-component system in Salmonella
por: Kato, Akinori, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7tpqc19e35pqck97cu0lcuscau